116 related articles for article (PubMed ID: 12017316)
1. Prognostic factors in non-small cell lung carcinoma.
Koutsami MK; Gorgoulis VG; Kastrinakis NG; Asimacopoulos PJ; Kittas C
Anticancer Res; 2002; 22(1A):347-74. PubMed ID: 12017316
[TBL] [Abstract][Full Text] [Related]
2. Prognostic value of exhaled microsatellite alterations at 3p in NSCLC patients.
Carpagnano GE; Spanevello A; Carpagnano F; Palladino GP; Prato R; Martinelli D; Digioia G; Foschino-Barbaro MP
Lung Cancer; 2009 Jun; 64(3):334-40. PubMed ID: 18995925
[TBL] [Abstract][Full Text] [Related]
3. Overexpression of Pokemon in non-small cell lung cancer and foreshowing tumor biological behavior as well as clinical results.
Zhao ZH; Wang SF; Yu L; Wang J; Chang H; Yan WL; Zhang J; Fu K
Lung Cancer; 2008 Oct; 62(1):113-9. PubMed ID: 18550205
[TBL] [Abstract][Full Text] [Related]
4. Tumour cell expression of C4.4A, a structural homologue of the urokinase receptor, correlates with poor prognosis in non-small cell lung cancer.
Hansen LV; Skov BG; Ploug M; Pappot H
Lung Cancer; 2007 Nov; 58(2):260-6. PubMed ID: 17706320
[TBL] [Abstract][Full Text] [Related]
5. Expression and prognostic significance of cyclin B1 and cyclin A in non-small cell lung cancer.
Cooper WA; Kohonen-Corish MR; McCaughan B; Kennedy C; Sutherland RL; Lee CS
Histopathology; 2009 Jul; 55(1):28-36. PubMed ID: 19614764
[TBL] [Abstract][Full Text] [Related]
6. Prognostic implications of cell cycle, apoptosis, and angiogenesis biomarkers in non-small cell lung cancer: a review.
Singhal S; Vachani A; Antin-Ozerkis D; Kaiser LR; Albelda SM
Clin Cancer Res; 2005 Jun; 11(11):3974-86. PubMed ID: 15930332
[TBL] [Abstract][Full Text] [Related]
7. Prognostic immune markers in non-small cell lung cancer.
Suzuki K; Kachala SS; Kadota K; Shen R; Mo Q; Beer DG; Rusch VW; Travis WD; Adusumilli PS
Clin Cancer Res; 2011 Aug; 17(16):5247-56. PubMed ID: 21659461
[TBL] [Abstract][Full Text] [Related]
8. Excision repair cross-complementation group 1 (ERCC1) in platinum-based treatment of non-small cell lung cancer with special emphasis on carboplatin: a review of current literature.
Vilmar A; Sørensen JB
Lung Cancer; 2009 May; 64(2):131-9. PubMed ID: 18804893
[TBL] [Abstract][Full Text] [Related]
9. Molecular profiling of lung carcinoma: identifying clinically useful tumor markers for diagnosis and prognosis.
Dacic S
Expert Rev Mol Diagn; 2007 Jan; 7(1):77-86. PubMed ID: 17187486
[TBL] [Abstract][Full Text] [Related]
10. Prognostic factors in non-small cell lung cancer.
Solan MJ; Werner-Wasik M
Semin Surg Oncol; 2003; 21(2):64-73. PubMed ID: 14508856
[TBL] [Abstract][Full Text] [Related]
11. Expression of pigment epithelial derived factor is reduced in non-small cell lung cancer and is linked to clinical outcome.
Zhang L; Chen J; Ke Y; Mansel RE; Jiang WG
Int J Mol Med; 2006 May; 17(5):937-44. PubMed ID: 16596284
[TBL] [Abstract][Full Text] [Related]
12. [Oncogenes, differentiation markers and morphological criteria as prognostic parameters in non-small-cell bronchial carcinoma].
Thomas M; Junker K
Dtsch Med Wochenschr; 1997 Oct; 122(43):1327-31. PubMed ID: 9410698
[No Abstract] [Full Text] [Related]
13. Centromere protein H is a novel prognostic marker for human nonsmall cell lung cancer progression and overall patient survival.
Liao WT; Wang X; Xu LH; Kong QL; Yu CP; Li MZ; Shi L; Zeng MS; Song LB
Cancer; 2009 Apr; 115(7):1507-17. PubMed ID: 19170237
[TBL] [Abstract][Full Text] [Related]
14. Prognosis of non-small cell lung cancer patients by detecting circulating cancer cells in the peripheral blood with multiple marker genes.
Sher YP; Shih JY; Yang PC; Roffler SR; Chu YW; Wu CW; Yu CL; Peck K
Clin Cancer Res; 2005 Jan; 11(1):173-9. PubMed ID: 15671543
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of different markers in non-small cell lung cancer: prognostic value of clinical staging, tumour cell detection and tumour marker analysis for tumour progression and overall survival.
Kasimir-Bauer S; Schleucher N; Weber R; Neumann R; Seeber S
Oncol Rep; 2003; 10(2):475-82. PubMed ID: 12579292
[TBL] [Abstract][Full Text] [Related]
16. [Retinoid expression (RARbeta and CRBP1) in non-small-cell lung carcinoma].
Mauro LV; Dalurzo M; Smith D; Lastiri J; Vasallo B; Joffei EB; Pallotta MG; Puricelli L
Medicina (B Aires); 2008; 68(3):205-12. PubMed ID: 18689151
[TBL] [Abstract][Full Text] [Related]
17. Involvement of epithelial cell transforming sequence-2 oncoantigen in lung and esophageal cancer progression.
Hirata D; Yamabuki T; Miki D; Ito T; Tsuchiya E; Fujita M; Hosokawa M; Chayama K; Nakamura Y; Daigo Y
Clin Cancer Res; 2009 Jan; 15(1):256-66. PubMed ID: 19118053
[TBL] [Abstract][Full Text] [Related]
18. Increased apolipoprotein E gene expression and protein concentration in lung cancer tissue do not contribute to the clinical assessment of non-small cell lung cancer patients.
Trost Z; Marc J; Sok M; Cerne D
Arch Med Res; 2008 Oct; 39(7):663-7. PubMed ID: 18760194
[TBL] [Abstract][Full Text] [Related]
19. Expression level of valosin-containing protein (p97) is correlated with progression and prognosis of non-small-cell lung carcinoma.
Yamamoto S; Tomita Y; Hoshida Y; Iizuka N; Monden M; Yamamoto S; Iuchi K; Aozasa K
Ann Surg Oncol; 2004 Jul; 11(7):697-704. PubMed ID: 15231524
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of the prognostic role of a panel of biomarkers in stage IB-IIIA non-small cell lung cancer patients.
Timotheadou E; Skarlos DV; Samantas E; Papadopoulos S; Murray S; Skrickova J; Christodoulou C; Papakostantinou C; Pectasides D; Papakostas P; Kaplanova J; Vrettou E; Karina M; Kosmidis P; Fountzilas G
Anticancer Res; 2007; 27(6C):4481-9. PubMed ID: 18214064
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
